The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, ...

Women with polycystic ovary syndrome and a diagnosis of depression are 56% more likely to develop metabolic syndrome compared ...

If antipsychotic polypharmacy, which is not recommended, is associated with a greater risk of metabolic syndrome, the spread of polypharmacy is a serious concern. However, it remains unclear among ...

“Previously, patients thought to be eligible for LAIs — also reflected in past guidelines — were chronically ill patients, those with multiple relapses, established nonadherence, or patients ...

Correspondence to Dr Yin Cao, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in Saint Louis, Saint Louis, MO 63110, USA; yin.cao{at}wustl.edu ...

Introduction: Antipsychotic-induced dyslipidemia represents a common adverse effect faced by patients with schizophrenia that increases risk for developing further metabolic complications and ...

Higher prevalence of physical comorbidity and premature mortality in persons with schizophrenia (PwS) results primarily from heightened cardiovascular and metabolic risks. The literature suggests that ...